Compare HCA Health Inc (HCA) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HCA Health Inc vs Incyte Corporation — how do they compare? HCA Health Inc trades at $442.02 (market cap $96.35B), while Incyte Corporation trades at $112.8 (market cap $22.85B). The key difference: HCA Health Inc is far larger — about 4.2× Incyte Corporation's market cap, and HCA Health Inc pays a 0.7% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold HCA Health Inc for 76 Days and Incyte Corporation for 33 Days on average.
| HCA | INCY | |
|---|---|---|
Market Cap | $96.35B | $22.85B |
Volume | 1,079,453 | 1,927,029 |
Sector | Health | Health |
52-Week High | $545.13 | $129.93 |
52-Week Low | $361.32 | $83.80 |
Typical Hold Time | 76 Days | 33 Days |
Enterprise Value | $146.88B | $18.35B |
Dividend Yield | 0.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HCA Healthcare (HCA) trades at $439.17, up 1.61% on the day, with a bullish technical signal and strong fundamentals. The stock shows consistent revenue growth, reaching $75.6B in 2025, and has beaten EPS estimates for three consecutive quarters. Analyst consensus is bullish with a $461.12 price target, supported by solid cash flow from operations of $12.64B and a net income margin of 8.77%.
The outlook remains positive given earnings momentum and operational efficiency, but risks include ongoing legal investigations and high debt levels. Upside potential exists if the company maintains its earnings beat streak and manages payer-mix challenges effectively.
Incyte (INCY) trades at $113.44, up 0.63% with a bullish technical outlook despite mixed moving average signals. The company shows strong fundamentals with $5.14B revenue, 27.71% net margin, and robust cash flow of $1.41B. Recent FDA approval for Atebrioz and pipeline expansion beyond JAKAFI position the company for growth, with analysts projecting $5.8B revenue and $1.6B net income for 2026.
The investment case centers on Incyte's successful diversification strategy and strong profitability metrics, though investors face risks from JAKAFI patent expiration in 2029 and near-term earnings volatility. With 52% analyst buy ratings and a $132.43 consensus price target representing 17% upside, the stock offers growth potential but requires monitoring of pipeline execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About HCA Health Inc
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
